Objective To estimate the association between the use of sodium glucose co-transporter-2
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …

Background: Multiple published quantitative systematic reviews have reported on adverse
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …

Introduction Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …

Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering
agent to be shown to reduce cardiovascular events. They are generally well tolerated with …

Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors have a well-defined safety
profile based on data obtained from numerous clinical trials, including cardiovascular …

Objective Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for
the treatment of diabetes. We aimed at describing the maximal benefits and risks associated …

Background The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on
cardiovascular outcomes have not been well established. We pooled evidence from all …

Objective To assess the association between the use of sodium glucose cotransporter 2
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …

Background The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors
across different patient groups have not been quantified. Methods We performed a meta …

Background: Sodium glucose co-transport 2 inhibitors (SGLT2-i) are the new class of
antidiabetic medications which are recently approved (2013) by the Food and Drug …